Latest Breaking News On - Cardurion pharmaceuticals inc - Page 1 : comparemela.com
Share:
Appointment reflects progress of Company s early-stage pipeline toward the clinic
Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer and head, translational medicine. Dr. Surks joins Cardurion from Sanofi where he most recently served as head, translational medicine and clinical pharmacology U.S. We are very gratified that Howard has decided to join the Cardurion team at a time when our early-stage pipeline is moving rapidly toward the clinic, said Peter Lawrence, chief executive officer of Cardurion. Howard s decades-long leadership encompassing cardiovascular drug discovery and development at Sanofi and Merck, and his basic cardiovascular research experience at Tufts Medical Center and School of Medicine
BostonMassachusettsUnited-statesJapanTufts-medical-centerPeter-lawrenceHowardk-surksCardurion-pharmaceuticals-incSchool-of-medicineCardurion-pharmaceuticalsMolecular-cardiology-research-instituteTufts-medical